Our recent technical analysis of Miromatrix Medical (USA Stocks:MIRO)

Every cloud has a silver lining, and this seems to be the case for Miromatrix Medical (NASDAQ: MIRO), a company operating in the Biotechnology industry. Despite reporting a loss of 30 million in Net Income From Continuing Ops and Operating Income, the company's shares have been on a bullish trend, showing signs of significant resilience. The company, which debuted on the NASDAQ on the 24th of June 2021, has seen its shares experience a 52 Week High of 4.5, while its 52 Week Low was registered at 0.9065. The 50 Day MA stands at 1.4808, indicating a steady upward momentum. The company's shares have a Short Ratio of 38.2, with Shares Short Prior Month at 527.2K and current Shares Short standing at 538.2K. Despite this, the Short Percent is only 0.0201, suggesting a low level of bearish sentiment. In terms of valuation, Miromatrix Medical has a Market Value of 3.34 and a Hype Value of 3.31, while its Real Value is estimated at 2.88. Despite the company's loss, the Wall Street Target Price is optimistic at 9, significantly higher than the Analyst Lowest Estimated Target Price of 3. In conclusion, given the bullish trend and the Strong Buy consensus among analysts, there's a chance that Miromatrix Medical's shares will continue their upward trajectory in December. While many baby boomers may be indifferent towards the biotechnology sector, it's worthwhile to examine Miromatrix Medical in the context of current market trends. Despite the market posting solid gains today, the long-term outlook for Miromatrix Medical may not be as promising. The company's stock price movements have largely mirrored the overall market trends. The firm's robust fundamental indicators suggest a potential short-term price swing for Miromatrix insiders. The next quarterly report is slated for release on November 13, 2023. Currently, the stock is experiencing above-average trading activity.
Published over three months ago
View all stories for Miromatrix Medical | View All Stories
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.

Reviewed by Raphi Shpitalnik

Miromatrix Medical (NASDAQ: MIRO), a prominent player in the Biotechnology industry, has been demonstrating a bullish trend in its stock performance, which is expected to continue into December. The company's shares have shown a steady increase, with the current quote at $3.34, which is close to the 52-week high of $4.5. Despite the company reporting a loss of $30M from continuing operations, Wall Street analysts have set a target price of $9 for the stock, indicating strong confidence in its future performance. From a risk-adjusted perspective, Miromatrix's Sortino Ratio of 0.5989 suggests that the company has been able to provide satisfactory returns for the level of risk it has taken on. Furthermore, the company's Treynor Ratio of 0.2451 indicates that it has generated decent risk-adjusted returns when considering the systematic risk. However, investors should be cautious of the company's high standard deviation of 27.21, which indicates a high level of volatility in the stock's returns. Despite the company's negative net income, the number of shares shorted in the prior month was 527.2K, suggesting that market sentiment towards the stock is bullish. The company's Price to Book ratio of 2.6176 is also within a reasonable range, indicating that the stock is not overvalued. Given these factors, it is likely that Miromatrix Medical's shares will continue their bullish trend in December.

Important Points

Miromatrix Medical has an average rating of 'Strong Buy' from one analyst. Is this consensus based on technical analysis? As we know, typical technical analysis involves the use of price momentum, patterns, and trends derived from historical prices. The goal is to identify signals based on the market sentiment of Miromatrix Medical investors, which reflects their perception of the company's future value. Let's delve into some aspects of Miromatrix's technical analysis. Approximately 24.0% of the company's outstanding shares are owned by corporate insiders. The book value of Miromatrix Medical is currently reported as 0.79. The company has recorded a loss per share of 1.26. It's important to note that Miromatrix Medical has not issued any dividends in recent years.
Using predictive technical analysis, we can analyze different prices and returns patterns and diagnose historical swings to determine the real value of Miromatrix Medical. In general, sophisticated investors focus on analyzing Miromatrix Medical stock price patterns and their correlations with different microeconomic environment and drivers. They apply predictive analytics to build Miromatrix Medical's daily price indicators and compare them against related drivers such as momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of Miromatrix Medical's intrinsic value. In addition to deriving basic predictive indicators for Miromatrix Medical, many experienced traders also check how macroeconomic factors affect Miromatrix Medical price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Miromatrix Medical's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Miromatrix Medical in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Miromatrix Medical. Your research has to be compared to or analyzed against Miromatrix Medical's peers to derive any actionable benefits. When done correctly, Miromatrix Medical's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Miromatrix Medical.

How important is Miromatrix Medical's Liquidity

Miromatrix Medical financial leverage refers to using borrowed capital as a funding source to finance Miromatrix Medical ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Miromatrix Medical financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Miromatrix Medical's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Miromatrix Medical's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Miromatrix Medical's total debt and its cash.

Closer look at Miromatrix Medical Standard Deviation

Miromatrix Medical has current Standard Deviation of 27.21. The Standard Deviation is a measure of how spread out the prices or returns of an asset are on average. It is the most widely used risk indicator in the field of investing and finance. Standard Deviation is commonly used to measure confidence in statistical conclusions regarding certain equity instruments or portfolios of equities.
Standard deviation is applied to the annual rate of return of an investment to measure the investment's volatility. Standard deviation is also known as historical volatility and is used by investors as a gauge for the amount of expected market volatility. A large standard deviation usually indicates that the data points are far from the mean and a small standard deviation indicates that they are clustered closely around the mean.
Standard Deviation 
=  
SQRT(V) 
 = 
27.21
SQRT = Square root notation
V =   Variance of Miromatrix Medical returns
Let's now compare Miromatrix Medical Standard Deviation to its closest peers:
MIRO
HNFSB
NIPMY
SIGRF
SSYS
MIRO27.209504698106397
HNFSB0.46
NIPMY0.008157
SIGRF0.76
SSYS2.92
Every cloud has a silver lining, and the silver lining for Miromatrix Medical (NASDAQ: MIRO) is its bullish trend, despite a challenging financial landscape.
The biotechnology company has seen a steady uptick in its 50-day moving average, which stands at 1.48, while its 200-day moving average is at 1.68. This indicates a positive momentum, which could continue into December. However, the company's financial health is a cause for concern. With a net income showing losses of 30M and an operating income showing losses of 30.2M, profitability is a challenge. Yet, Miromatrix Medical's current ratio is at an impressive 9.09X, indicating the company's strong ability to meet its short-term obligations. The company's market capitalization stands at 91.58M, reflecting its perceived value by the market. Despite the financial challenges, the company's shares are expected to continue their bullish trend, given the favorable technicals. .

Miromatrix is expecting lower volatility in December

Miromatrix Medical Inc., a notable entity in the biotechnology sector, is currently exhibiting signs of decreased volatility as we transition into December. The potential upside of the stock has been revised downwards to 10.61, signaling a more stable and less risky investment landscape. This revision implies that investors can anticipate fewer price swings, thus providing a more predictable investment prospect. Despite the reduced upside, Miromatrix remains a worthwhile investment, particularly for those seeking stability in the typically volatile biotech sector. Miromatrix Medical is demonstrating above-average volatility over the chosen time period. Investors are advised to examine Miromatrix Medical independently to ensure that their intended market timing strategies align with their expectations about Miromatrix Medical's volatility. Understanding varying market volatility trends often assists investors in timing the market. The correct use of volatility indicators allows traders to gauge Miromatrix Medical's stock risk against market volatility during both bullish and bearish trends. The heightened level of volatility that accompanies bear markets can directly affect Miromatrix Medical's stock price, adding stress to investors as they witness the value of their shares plummet. This typically compels investors to rebalance their portfolios by purchasing different stocks as prices decline.

Our Final Take On Miromatrix Medical

Although some companies within the biotechnology industry are still a little expensive, even after the recent corrections, Miromatrix Medical may offer a potential longer-term growth to insiders. With an impartial outlook on the current market volatility, it may be better to hold off any inventment activity and neither buy nor drop any shares of Miromatrix Medical at this time. The Miromatrix Medical risk-reward trade off is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Miromatrix Medical.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Rifka Kats do not own shares of Miromatrix Medical. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com